{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - The guideline recommends against routine use of ursodeoxycholic acid (UDCA) for adverse perinatal outcomes in ICP, yet the note prescribes UDCA 500 mg BID.  \n   Reason: The guideline states \"No treatments improve pregnancy outcomes or reduce bile acid concentrations\" and specifically advises \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\"  \n\n2. **Different management plan** - The guideline does not support routine fetal surveillance (CTG/growth scans) for predicting or preventing stillbirth in ICP, yet the note plans twice-weekly CTGs and weekly growth scans.  \n   Reason: The guideline explicitly states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\"  \n\n3. **Improved patient advice** - The note discusses increased stillbirth risk but does not quantify the risk based on bile acid levels (e.g., significantly higher risk if ≥100 µmol/L).  \n   Reason: The guideline emphasizes counseling on \"planned birth timing\" based on peak bile acid concentrations and notes the higher risk in twin pregnancies.  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - The note omits baseline bile acid levels from booking bloods, which are recommended for establishing normal levels in subsequent pregnancies.  \n   Reason: The guideline states \"In subsequent pregnancies, baseline measurement of liver function tests and bile acid concentrations should be performed to establish normal levels.\"  \n\n2. **Different management plan** - The note considers chlorphenamine for itching, but the guideline prioritizes topical emollients/antihistamines for symptom relief without specifying systemic antihistamines.  \n   Reason: The guideline recommends \"Drug treatments for ICP, such as topical emollients and antihistamines, can help alleviate symptoms.\"  \n\n3. **Additional information needed** - No mention of monitoring for pre-eclampsia or gestational diabetes, which are higher-risk comorbidities in ICP.  \n   Reason: The guideline notes women with ICP have a higher chance of these conditions and \"should have regular monitoring.\"  \n\n### Less Important Recommendations\n1. **Improved patient advice** - The note provides written information but could specify ICP Support/RCOG resources per the guideline.  \n   Reason: The guideline lists \"Information for women and families from ICP Support and RCOG\" as useful links.  \n\n2. **Additional information needed** - No documentation of postnatal follow-up plans to confirm resolution of ICP.  \n   Reason: The guideline recommends \"Follow-up should be arranged at least 4 weeks postpartum... to confirm resolution.\"  \n\n### Unimportant Recommendations\n1. **Improved patient advice** - The note could clarify that vitamin K is only needed if steatorrhea or coagulopathy is present.  \n   Reason: The guideline states \"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\"  \n\n### Summary of Critical Gaps:\n- **Overuse of interventions**: UDCA and fetal surveillance are not evidence-based per the guideline.  \n- **Incomplete counseling**: Lack of risk stratification by bile acid levels.  \n- **Missing baseline/comorbidity data**: No booking bile acids or monitoring for pre-eclampsia/gestational diabetes.  \n\nThe note aligns well with delivery planning (36–37 weeks) and movement monitoring but requires significant adjustments to de-emphasize non-beneficial interventions and strengthen patient counseling.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 59 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 3943,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider discontinuing ursodeoxycholic acid as it is not routinely recommended for adverse perinatal outcomes in ICP.\",\n      \"context\": \"Guideline states no treatments improve pregnancy outcomes or reduce bile acid concentrations in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reduce surveillance to fetal movement monitoring only, as CTGs/growth scans do not predict or prevent stillbirth in ICP\",\n      \"context\": \"Guideline states fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Quantify stillbirth risk based on bile acid levels (e.g., significantly higher risk if ≥100 µmol/L) during counseling\",\n      \"context\": \"Guideline emphasizes counseling on planned birth timing based on peak bile acid concentrations\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Counseling should include planned birth timing based on peak bile acid concentrations\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for future reference\",\n      \"context\": \"Guideline recommends baseline measurement in subsequent pregnancies to establish normal levels\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"In subsequent pregnancies, baseline measurement of bile acid concentrations should be performed\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Consider chlorphenamine for symptomatic relief of itching.\",\n      \"suggestedText\": \"Consider topical emollients/first-line antihistamines instead of systemic chlorphenamine\",\n      \"context\": \"Guideline prioritizes topical treatments over systemic antihistamines\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Drug treatments for ICP, such as topical emollients and antihistamines, can help alleviate symptoms\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Missing: monitoring for pre-eclampsia or gestational diabetes\",\n      \"suggestedText\": \"Add monitoring for pre-eclampsia and gestational diabetes given higher risk in ICP\",\n      \"context\": \"Guideline notes women with ICP have higher chance of these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Women with ICP should have regular monitoring for pre-eclampsia and gestational diabetes\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Provided written information and contact details for triage if symptoms worsen.\",\n      \"suggestedText\": \"Include specific ICP Support/RCOG resources in written information provided\",\n      \"context\": \"Guideline lists these as useful resources for patients\",\n      \"category\": \"modification\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Information for women and families from ICP Support and RCOG\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Missing: postnatal follow-up plans\",\n      \"suggestedText\": \"Document plans for postnatal follow-up at least 4 weeks postpartum to confirm ICP resolution\",\n      \"context\": \"Guideline recommends follow-up to confirm resolution of ICP\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Follow-up should be arranged at least 4 weeks postpartum to confirm resolution\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-10T19-48-50",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - The guideline recommends against routine use of ursodeoxycholic acid (UDCA) for adverse perinatal outcomes in ICP, yet the note prescribes UDCA 500 mg BID.  \\n   Reason: The guideline states \\\"No treatments improve pregnancy outcomes or reduce bile acid concentrations\\\" and specifically advises \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\\\"  \\n\\n2. **Different management plan** - The guideline does not support routine fetal surveillance (CTG/growth scans) for predicting or preventing stillbirth in ICP, yet the note plans twice-weekly CTGs and weekly growth scans.  \\n   Reason: The guideline explicitly states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\\\"  \\n\\n3. **Improved patient advice** - The note discusses increased stillbirth risk but does not quantify the risk based on bile acid levels (e.g., significantly higher risk if ≥100 µmol/L).  \\n   Reason: The guideline emphasizes counseling on \\\"planned birth timing\\\" based on peak bile acid concentrations and notes the higher risk in twin pregnancies.  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - The note omits baseline bile acid levels from booking bloods, which are recommended for establishing normal levels in subsequent pregnancies.  \\n   Reason: The guideline states \\\"In subsequent pregnancies, baseline measurement of liver function tests and bile acid concentrations should be performed to establish normal levels.\\\"  \\n\\n2. **Different management plan** - The note considers chlorphenamine for itching, but the guideline prioritizes topical emollients/antihistamines for symptom relief without specifying systemic antihistamines.  \\n   Reason: The guideline recommends \\\"Drug treatments for ICP, such as topical emollients and antihistamines, can help alleviate symptoms.\\\"  \\n\\n3. **Additional information needed** - No mention of monitoring for pre-eclampsia or gestational diabetes, which are higher-risk comorbidities in ICP.  \\n   Reason: The guideline notes women with ICP have a higher chance of these conditions and \\\"should have regular monitoring.\\\"  \\n\\n### Less Important Recommendations\\n1. **Improved patient advice** - The note provides written information but could specify ICP Support/RCOG resources per the guideline.  \\n   Reason: The guideline lists \\\"Information for women and families from ICP Support and RCOG\\\" as useful links.  \\n\\n2. **Additional information needed** - No documentation of postnatal follow-up plans to confirm resolution of ICP.  \\n   Reason: The guideline recommends \\\"Follow-up should be arranged at least 4 weeks postpartum... to confirm resolution.\\\"  \\n\\n### Unimportant Recommendations\\n1. **Improved patient advice** - The note could clarify that vitamin K is only needed if steatorrhea or coagulopathy is present.  \\n   Reason: The guideline states \\\"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\\\"  \\n\\n### Summary of Critical Gaps:\\n- **Overuse of interventions**: UDCA and fetal surveillance are not evidence-based per the guideline.  \\n- **Incomplete counseling**: Lack of risk stratification by bile acid levels.  \\n- **Missing baseline/comorbidity data**: No booking bile acids or monitoring for pre-eclampsia/gestational diabetes.  \\n\\nThe note aligns well with delivery planning (36–37 weeks) and movement monitoring but requires significant adjustments to de-emphasize non-beneficial interventions and strengthen patient counseling.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 59 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 3943,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider discontinuing ursodeoxycholic acid as it is not routinely recommended for adverse perinatal outcomes in ICP.\",\n      \"context\": \"Guideline states no treatments improve pregnancy outcomes or reduce bile acid concentrations in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reduce surveillance to fetal movement monitoring only, as CTGs/growth scans do not predict or prevent stillbirth in ICP\",\n      \"context\": \"Guideline states fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Quantify stillbirth risk based on bile acid levels (e.g., significantly higher risk if ≥100 µmol/L) during counseling\",\n      \"context\": \"Guideline emphasizes counseling on planned birth timing based on peak bile acid concentrations\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Counseling should include planned birth timing based on peak bile acid concentrations\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for future reference\",\n      \"context\": \"Guideline recommends baseline measurement in subsequent pregnancies to establish normal levels\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"In subsequent pregnancies, baseline measurement of bile acid concentrations should be performed\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Consider chlorphenamine for symptomatic relief of itching.\",\n      \"suggestedText\": \"Consider topical emollients/first-line antihistamines instead of systemic chlorphenamine\",\n      \"context\": \"Guideline prioritizes topical treatments over systemic antihistamines\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Drug treatments for ICP, such as topical emollients and antihistamines, can help alleviate symptoms\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Missing: monitoring for pre-eclampsia or gestational diabetes\",\n      \"suggestedText\": \"Add monitoring for pre-eclampsia and gestational diabetes given higher risk in ICP\",\n      \"context\": \"Guideline notes women with ICP have higher chance of these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Women with ICP should have regular monitoring for pre-eclampsia and gestational diabetes\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Provided written information and contact details for triage if symptoms worsen.\",\n      \"suggestedText\": \"Include specific ICP Support/RCOG resources in written information provided\",\n      \"context\": \"Guideline lists these as useful resources for patients\",\n      \"category\": \"modification\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Information for women and families from ICP Support and RCOG\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Missing: postnatal follow-up plans\",\n      \"suggestedText\": \"Document plans for postnatal follow-up at least 4 weeks postpartum to confirm ICP resolution\",\n      \"context\": \"Guideline recommends follow-up to confirm resolution of ICP\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Follow-up should be arranged at least 4 weeks postpartum to confirm resolution\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1959\nCompletion tokens: 914\nTotal tokens: 2873\nEstimated cost: $0.001437",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1959,
    "completion_tokens": 914,
    "total_tokens": 2873,
    "estimated_cost_usd": 0.0014365000000000003
  }
}